Mesa Verde Venture Partners

Mesa Verde Venture Partners is a venture capital firm founded in 2006 and based in San Diego, California. The firm specializes in seed and early-stage investments, primarily targeting companies in the biomedical, life sciences, biotechnology, and medical technology sectors. Its investment focus includes therapeutics, medical devices, diagnostics, life science tools, healthcare wireless solutions, and healthcare information technology. Mesa Verde Venture Partners typically invests between $0.25 million and $1 million, with a preference for opportunities in Southern California and the Southwestern United States. The firm aims to build a diversified portfolio of early-stage companies that are poised for growth in the life sciences and medical technology industries.

Carey Ng

Managing Director

23 past transactions

Immusoft

Venture Round in 2020
Immusoft Corporation is a biotechnology company based in Seattle, Washington, focused on developing autologous cell therapies for various human diseases through its proprietary Immune System Programming (ISP) technology. Founded in 2009, the company modifies a patient's immune cells, specifically B cells, to create miniature drug factories that produce gene-encoded medicines, or biologics. By reprogramming these cells, Immusoft's technology enables the in vivo delivery of therapeutics that can replace missing or defective enzymes and proteins. The core ISP technology was initially developed at the California Institute of Technology and is exclusively licensed to Immusoft. This innovative approach aims to improve treatments for rare and infectious diseases by harnessing the body's own immune system.

CalciMedica

Series C in 2020
CalciMedica, Inc. is a biotechnology company based in La Jolla, California, focused on the discovery and development of small molecule drugs aimed at treating autoimmune and inflammatory diseases. Founded in December 2006 by a team of scientists with backgrounds in calcium signaling, the company specializes in the targeted inhibition of calcium release-activated calcium channels, a key mechanism in immune response regulation. The founding team includes individuals who previously collaborated at TorreyPines Therapeutics and the CBR Institute, where they made significant contributions to understanding calcium signaling pathways. Through its innovative research, CalciMedica aims to develop effective therapies for patients suffering from various autoimmune conditions.

Immix Biopharma

Venture Round in 2019
Immix Biopharma, Inc. is a biopharmaceutical company based in Los Angeles, California, founded in 2014, that focuses on developing innovative therapies for cancer patients, particularly those resistant to chemotherapy and immunotherapy. The company’s portfolio includes several product candidates: Imx-109, a small-molecule designed to enhance the effectiveness of various cancer treatments; Imx-110, a nanoparticle delivery system that combines a cytotoxin with a potent agent to improve synergy with established chemotherapy drugs; Imx-111, a targeted variant of Imx-110; and Imx-004, a humanized antibody targeting an undisclosed antigen prevalent in various tumors. Immix Biopharma aims to create multi-component drug candidates to address the complex needs of cancer treatment and improve patient outcomes.

NeuraLace Medical

Seed Round in 2019
NeuraLace Medical, Inc., founded in 2016 and headquartered in San Diego, California, focuses on developing a hardware-based neuromodulation platform aimed at the management of neuropathic pain. The company is creating a non-invasive interface that selectively stimulates sensory nerve fibers, providing a potential solution for chronic pain relief. By bridging the gap between technology and neurology, NeuraLace Medical aims to deliver effective pain management solutions on a broader scale.

Paradigm Diagnostics

Series B in 2019
Paradigm Diagnostics specializes in advanced cancer diagnostics and biomarker-driven clinical trials, aiming to enhance treatment options for cancer patients. Utilizing next-generation sequencing and comprehensive biomarker analysis, Paradigm assesses the genomic and proteomic characteristics of individual tumors. This information allows for a detailed understanding of the specific cancer pathways involved and the potential therapies tailored to each patient's unique tumor profile. By focusing on personalized medicine, Paradigm empowers healthcare providers to offer targeted treatment strategies, ultimately improving patient outcomes in cancer care.

Immusoft

Series B in 2019
Immusoft Corporation is a biotechnology company based in Seattle, Washington, focused on developing autologous cell therapies for various human diseases through its proprietary Immune System Programming (ISP) technology. Founded in 2009, the company modifies a patient's immune cells, specifically B cells, to create miniature drug factories that produce gene-encoded medicines, or biologics. By reprogramming these cells, Immusoft's technology enables the in vivo delivery of therapeutics that can replace missing or defective enzymes and proteins. The core ISP technology was initially developed at the California Institute of Technology and is exclusively licensed to Immusoft. This innovative approach aims to improve treatments for rare and infectious diseases by harnessing the body's own immune system.

Paradigm Diagnostics

Series B in 2018
Paradigm Diagnostics specializes in advanced cancer diagnostics and biomarker-driven clinical trials, aiming to enhance treatment options for cancer patients. Utilizing next-generation sequencing and comprehensive biomarker analysis, Paradigm assesses the genomic and proteomic characteristics of individual tumors. This information allows for a detailed understanding of the specific cancer pathways involved and the potential therapies tailored to each patient's unique tumor profile. By focusing on personalized medicine, Paradigm empowers healthcare providers to offer targeted treatment strategies, ultimately improving patient outcomes in cancer care.

Biscayne Pharmaceuticals

Series B in 2017
Biscayne Pharmaceuticals, Inc. is a biopharmaceutical company based in Miami, Florida, focused on developing therapies that leverage growth hormone-releasing hormone (GHRH) analogs. The company is engaged in creating GHRH antagonists aimed at treating various cancers, including castrate-resistant prostate cancer, and GHRH agonists intended for cardiac repair in patients with heart disease. Additionally, Biscayne Pharmaceuticals is involved in developing drugs for refractory epilepsy and drug-resistant cancer by targeting GHRH receptors, which play a critical role in stimulating growth hormone production for tissue growth and repair. Since its incorporation in 2012, the company has aimed to provide innovative treatments for patients with challenging medical conditions.
Biscayne Neurotherapeutics is a clinical-stage biotechnology company developing novel therapies for difficult-to-treat neurological disorders. Biscayne’s lead compound, BIS-001, is in clinical development for the treatment of refractory forms of epilepsy. Biscayne Neurotherapeutics has an experienced executive team with an extensive track record of successful drug development, and its scientific advisors include a number of highly respected experts studying seizure and other CNS disorders. The company is headquartered in Miami, Florida, and benefits from the growing entrepreneurial South Florida biomedical sector.

Lineagen

Series C in 2015
Lineagen, Inc. is a genetics diagnostic company based in Salt Lake City, Utah, specializing in genetic testing and clinical information services for neurodevelopmental disorders, particularly autism. Founded in 2002, the company offers a range of diagnostic tools, including FirstStepDx PLUS, a chromosomal microarray platform designed to identify genomic changes related to autism and other neurodevelopmental disorders, and NextStepDx PLUS, a genetic sequencing test for detecting small genomic alterations. Additionally, Lineagen provides M-CHAT.org, an online screening resource for developmental evaluation. The company focuses on improving outcomes for individuals with autism and other complex diseases by enabling early diagnosis and intervention. Lineagen's research capabilities are enhanced by its access to the Utah Population Database through the University of Utah, which supports significant discoveries in disease-related genetics. As of August 2020, Lineagen operates as a subsidiary of Bionano Genomics, Inc.

Lineagen

Series C in 2013
Lineagen, Inc. is a genetics diagnostic company based in Salt Lake City, Utah, specializing in genetic testing and clinical information services for neurodevelopmental disorders, particularly autism. Founded in 2002, the company offers a range of diagnostic tools, including FirstStepDx PLUS, a chromosomal microarray platform designed to identify genomic changes related to autism and other neurodevelopmental disorders, and NextStepDx PLUS, a genetic sequencing test for detecting small genomic alterations. Additionally, Lineagen provides M-CHAT.org, an online screening resource for developmental evaluation. The company focuses on improving outcomes for individuals with autism and other complex diseases by enabling early diagnosis and intervention. Lineagen's research capabilities are enhanced by its access to the Utah Population Database through the University of Utah, which supports significant discoveries in disease-related genetics. As of August 2020, Lineagen operates as a subsidiary of Bionano Genomics, Inc.

Exagen

Debt Financing in 2013
Exagen is a patient focused, discovery-driven life science company that addresses the unmet need for the accurate diagnosis and monitors patients affected by autoimmune rheumatic diseases. The company also provides AVISE tests that are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis, and better disease management. Exagen was established in 2002 and is headquartered in Vista, California.

Exagen

Series C in 2012
Exagen is a patient focused, discovery-driven life science company that addresses the unmet need for the accurate diagnosis and monitors patients affected by autoimmune rheumatic diseases. The company also provides AVISE tests that are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis, and better disease management. Exagen was established in 2002 and is headquartered in Vista, California.

Elevation Pharmaceuticals

Series B in 2012
Founded in 2008, Elevation Pharmaceuticals is developing a pipeline of improved aerosol drug products for COPD patients. There founding team has a successful track record starting companies and building dedicated teams to develop new drug products that improve patients' lives. At Elevation, they have a disciplined approach to strategic decision-making that helps us stay focused on the path with the highest probability of success. They are executing our drug development plans with passion, integrity, and a high sense of urgency in order to meet the needs and expectations of our stakeholders -- employees, investors, partners, and patients.

Lineagen

Series B in 2011
Lineagen, Inc. is a genetics diagnostic company based in Salt Lake City, Utah, specializing in genetic testing and clinical information services for neurodevelopmental disorders, particularly autism. Founded in 2002, the company offers a range of diagnostic tools, including FirstStepDx PLUS, a chromosomal microarray platform designed to identify genomic changes related to autism and other neurodevelopmental disorders, and NextStepDx PLUS, a genetic sequencing test for detecting small genomic alterations. Additionally, Lineagen provides M-CHAT.org, an online screening resource for developmental evaluation. The company focuses on improving outcomes for individuals with autism and other complex diseases by enabling early diagnosis and intervention. Lineagen's research capabilities are enhanced by its access to the Utah Population Database through the University of Utah, which supports significant discoveries in disease-related genetics. As of August 2020, Lineagen operates as a subsidiary of Bionano Genomics, Inc.

Elevation Pharmaceuticals

Series A in 2011
Founded in 2008, Elevation Pharmaceuticals is developing a pipeline of improved aerosol drug products for COPD patients. There founding team has a successful track record starting companies and building dedicated teams to develop new drug products that improve patients' lives. At Elevation, they have a disciplined approach to strategic decision-making that helps us stay focused on the path with the highest probability of success. They are executing our drug development plans with passion, integrity, and a high sense of urgency in order to meet the needs and expectations of our stakeholders -- employees, investors, partners, and patients.

Exagen

Venture Round in 2011
Exagen is a patient focused, discovery-driven life science company that addresses the unmet need for the accurate diagnosis and monitors patients affected by autoimmune rheumatic diseases. The company also provides AVISE tests that are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis, and better disease management. Exagen was established in 2002 and is headquartered in Vista, California.

Exagen

Venture Round in 2011
Exagen is a patient focused, discovery-driven life science company that addresses the unmet need for the accurate diagnosis and monitors patients affected by autoimmune rheumatic diseases. The company also provides AVISE tests that are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis, and better disease management. Exagen was established in 2002 and is headquartered in Vista, California.

Lineagen

Series A in 2010
Lineagen, Inc. is a genetics diagnostic company based in Salt Lake City, Utah, specializing in genetic testing and clinical information services for neurodevelopmental disorders, particularly autism. Founded in 2002, the company offers a range of diagnostic tools, including FirstStepDx PLUS, a chromosomal microarray platform designed to identify genomic changes related to autism and other neurodevelopmental disorders, and NextStepDx PLUS, a genetic sequencing test for detecting small genomic alterations. Additionally, Lineagen provides M-CHAT.org, an online screening resource for developmental evaluation. The company focuses on improving outcomes for individuals with autism and other complex diseases by enabling early diagnosis and intervention. Lineagen's research capabilities are enhanced by its access to the Utah Population Database through the University of Utah, which supports significant discoveries in disease-related genetics. As of August 2020, Lineagen operates as a subsidiary of Bionano Genomics, Inc.

Elevation Pharmaceuticals

Series A in 2010
Founded in 2008, Elevation Pharmaceuticals is developing a pipeline of improved aerosol drug products for COPD patients. There founding team has a successful track record starting companies and building dedicated teams to develop new drug products that improve patients' lives. At Elevation, they have a disciplined approach to strategic decision-making that helps us stay focused on the path with the highest probability of success. They are executing our drug development plans with passion, integrity, and a high sense of urgency in order to meet the needs and expectations of our stakeholders -- employees, investors, partners, and patients.

Traversa Therapeutics

Series B in 2009
Traversa Therapeutics, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi Delivery Technologies. The company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a wide variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of this platform delivery technology, as well as advancement of its own therapeutic programs for the treatment of Leukemia and Glioblastoma.

Lineagen

Series A in 2008
Lineagen, Inc. is a genetics diagnostic company based in Salt Lake City, Utah, specializing in genetic testing and clinical information services for neurodevelopmental disorders, particularly autism. Founded in 2002, the company offers a range of diagnostic tools, including FirstStepDx PLUS, a chromosomal microarray platform designed to identify genomic changes related to autism and other neurodevelopmental disorders, and NextStepDx PLUS, a genetic sequencing test for detecting small genomic alterations. Additionally, Lineagen provides M-CHAT.org, an online screening resource for developmental evaluation. The company focuses on improving outcomes for individuals with autism and other complex diseases by enabling early diagnosis and intervention. Lineagen's research capabilities are enhanced by its access to the Utah Population Database through the University of Utah, which supports significant discoveries in disease-related genetics. As of August 2020, Lineagen operates as a subsidiary of Bionano Genomics, Inc.

Medipacs

Venture Round in 2008
Medipacs, Inc. is a company specializing in the development of non-mechanical infusion pumps designed to administer a variety of medications, including biologic drugs, insulin, hormones, fertility treatments, anti-coagulation agents, and pain relief medications. Founded in 2004, Medipacs is headquartered in San Diego, California, and operates research facilities in Tucson, Arizona. The company's innovative approach aims to enhance the delivery of essential therapies in a more efficient and effective manner.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.